EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China

Abstract

Authors

L. Chen B. Tan X. Gao K. Zhou J. Zhao J. Xuan

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×